Flavonoids

Metabolism of Drugs and Other Xenobiotics

Volumn , Issue , 2012, Pages 543-582

  Hodek, Petr ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Absorption; Biosynthesis; Classification; Diet; Drug; Flavonoid; Health; Metabolism

Indexed keywords

EID: 84887168703     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527630905.ch20     Document Type: Chapter

References (146)

1. Pietta, P.G. (2000) Flavonoids as antioxidants. J. Nat. Prod., 63, 1035-1042.
2. Andersen, Ø.M. and Markham, K.R. (2006) Flavonoids:Chemistry, Biochemistry and Applications, CRC Press, Boca Raton, FL.
3. Rice-Evans, C.A., Miller, N.J., and Paganga, G. (1996) Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radic. Biol. Med., 20, 933-956.
4. Bohm, B.A. (1998) Flavonoid functions in nature, in Introduction to Flavonoids (ed. B.A. Bohm), Harwood, Amsterdam, pp. 339-365.
5. Treutter, D. (2006) Significance of flavonoids in plant resistance:a review. Environ. Chem. Lett., 4, 147-157.
6. Packer, L. and Sies, H., eds (2001) Flavonoids and other polyphenols, in Methods in Enzymology 335, Academic Press, New York.
7. Stafford, H.A. (1990) Flavonoid Metabolism, CRC Press, Boca Raton, FL.
8. Manach, C., Scalbert, A., Morand, C., Remesy, C., and Jimenez, L. (2004) Polyphenols:food sources and bioavailability. Am.J. Clin. Nutr., 79, 727-747.
9. Kuhnau, J. (1976) The flavonoids. A class of semi-essential food components:their role in human nutrition. World Rev. Nutr. Diet., 24, 117-191.
10. Clifford, M.N. (2004) Diet-derived phenols in plasma and tissues and their implications for health. Planta Med., 70, 1103-1114.
11. Heinonen, M. (2001) Anthocyanins as dietary antioxidants, Proceedings of the Third International Conference on Natural Antioxidants and Anticarcinogens in Food, Health, and Disease, Helsinki.
12. Sampson, L., Rimm, E., Hollman, P.C., de Vries, J.H., and Katan, M.B. (2002) Flavonol and flavone intakes in US health professionals. J. Am. Diet. Assoc., 102, 1414-1420.
13. Kimira, M., Arai, Y., Shimoi, K., and Watanabe, S. (1998) Japanese intake of flavonoids and isoflavonoids from foods. J. Epidemiol., 8, 168-175.
14. Spencer, J.P.E., Rice-Evans, C.A., and Singh Srai, S.K. (2003) Metabolism in the small intestine and gastrointestinal tract, in Flavonoids in Health and Disease (eds L. Packer and C.A. Rice-Evans), Dekker, New York, pp. 363-391.
15. Erlund, I., Kosonen, T., Alfthan, G., Maaenpaa, J., Perttunen, K., Kenraali, J., Parantainen, J., and Aro, A. (2000) Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. Eur.J. Clin. Pharmacol., 56, 545-553.
16. Xing, J., Chen, X., and Zhong, D. (2005) Absorption and enterohepatic circulation of baicalin in rats. Life Sci., 78, 140-146.
17. Walle, T., Otake, Y., Brubaker, J.A., Walle, U.K., and Halushka, P.V. (2001) Disposition and metabolism of the flavonoid chrysin in normal volunteers. Br. J. Clin. Pharmacol., 51, 143-146.
18. Scalbert, A. and Williamson, G. (2000) Dietary intake and bioavailability of polyphenols. J. Nutr., 130, 2073S-2085S.
19. Vaidyanathan, J.B. and Walle, T. (2003) Cellular uptake and efflux of the tea flavonoid (-)-epicatechin-3-gallate in the human intestinal cell line Caco-2. J. Pharmacol. Exp. Ther., 307, 745-752.
20. Walle, T. (2004) Absorption and metabolism of flavonoids. Free Radic. Biol. Med., 36, 829-837.
21. Walle, T., Walle, U.K., and Halushka, P.V. (2001) Carbon dioxide is the major metabolite of quercetin in humans. J. Nutr., 131, 2648-2652.
22. Hollman, P.C., Bijsman, M.N., van Gameren, Y., Cnossen, E.P., de Vries, J.H., and Katan, M.B. (1999) The sugar moiety is a major determinant of the absorption of dietary flavonoid glycosides in man. Free Radic. Res., 31, 569-573.
23. Day, A.J., Canada, F.J., Diaz, J.C., Kroon, P.A., Mclauchlan, R., Faulds, C.B., Plumb, G.W., Morgan, M.R., and Williamson, G. (2000) Dietary flavonoid and isoflavone glycosides are hydrolysed by the lactase site of lactase phlorizin hydrolase. FEBS Lett., 468, 166-170.
24. Cheng, Z., Radominska-Pandya, A., and Tephly, T.R. (1999) Studies on the substrate specificity of human intestinal UDP-lucuronosyltransferases 1A8 and 1A10. Drug Metab. Dispos., 27, 1165-1170.
25. Paine, M.F., Hart, H.L., Ludington, S.S., Haining, R.L., Rettie, A.E., and Zeldin, D.C. (2006) The human intestinal cytochrome P450 "pie". Drug Metab. Dispos., 34, 880-886.
26. Setchell, K.D. and Clerici, C. (2010) Equol:history, chemistry, and formation. J. Nutr., 140, 1355S-1362S.
27. Prior, R.L., Wu, X., and Gu, L. (2006) Flavonoid metabolism and challenges to understanding mechanisms of health effects. J. Sci. Food Agric., 86, 2487-2491.
28. Nielsen, S.E., Breinholt, V.M., Justesen, U., Cornett, C., and Dragsted, L.O. (1998) In vitro biotransformation of flavonoids by rat liver microsomes. Xenobiotica, 28, 389-401.
29. Cermak, R. and Wolffram, S. (2006) The potential of flavonoids to influence drug metabolism and pharmacokinetics by local gastrointestinal mechanisms. Curr. Drug Metab., 7, 729-744.
30. Nielsen, S.E., Breinholt, V.M., Cornett, C., and Dragsted, L.O. (2000) Biotransformation of the citrus flavone tangeretin in rats. Identification of metabolites with intact flavane nucleus. Food Chem. Toxicol, 38, 739-746.
31. Sfakianos, J., Coward, L., Kirk, M., and Barnes, S. (1997) Intestinal uptake and biliary excretion of the isoflavone genistein in rats. J. Nutr., 127, 1260-1268.
32. 3H]epigallocatechin gallate and its metabolic fate in rats after intravenous administration. J. Agric. Food Chem., 49, 1042-1048.
33. 13C3]isoflavone internal standards. Anal. Biochem., 309, 158-172.
34. Chow, H.-H.S., Cai, Y., Albert, D.S., Hakim, I., Dorr, R., Shahi, F., Crowell, J., Yang, C., and Hara, Y. (2001) Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. Cancer Epidemiol. Biomark. Prev., 10, 53-58.
35. Manach, C., Williamson, G., Morand, C., Scalbert, A., and Remesy, C. (2005) Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am. J. Clin. Nutr., 81, 230S-242S.
36. Clifford, M. and Brown, J.E. (2006) Dietary flavonoids and health-broadening the perspective, in Flavonoids:Chemistry, Biochemistry and Applications (eds Ø.M. Andersen and K.R. Markham), CRC Press, Boca Raton, FL, pp. 320-344.
37. Walle, T. (2009) Methylation of dietary flavones increases their metabolic stability and chemopreventive effects. Int. J. Mol. Sci., 10, 5002-5019.
38. Donovan, J.L. and Waterhouse, A.L. (2003) Bioavailability of flavanol monomers, in Flavonoids in Health and Disease (eds L. Packer and C.A. Rice-Evans), Dekker, New York, pp. 413-441.
39. Han, X., Shen, T., and Lou, H. (2007) Dietary polyphenols and their biological significance. Int. J. Mol. Sci., 8, 950-988.
40. Hodek, P., Krizkova, J., Burdova, K., Sulc, M., Kizek, R., Hudecek, J., and Stiborova, M. (2009) Chemopreventive compounds-view from the other side. Chem. Biol. Interact., 180, 1-9.
41. Dangles, O. and Dufour, C. (2006) Flavonoid-protein interactions, in Flavonoids:Chemistry, Biochemistry and Applications (eds Ø.M. Andersen and K.R. Markham), CRC Press, Boca Raton, FL, pp. 443-464.
42. Bolli, A., Marino, M., Rimbach, G., Fanali, G., Fasano, M., and Ascenzi, P. (2010) Flavonoid binding to human serum albumin. Biochem. Biophys. Res. Commun., 398, 444-449.
43. Perez-Tomas, R. (2006) Multidrug resistance:retrospect and prospects in anti-cancer drug treatment. Curr. Med. Chem., 13, 1859-1876.
44. Zhang, S. and Morris, M.E. (2003) Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J. Pharmacol. Exp. Ther., 304, 1258-1267.
45. Kitagawa, S. (2006) Inhibitory effects of polyphenols on P-glycoprotein-mediated transport. Biol. Pharm. Bull., 29, 1-6.
46. Critchfield, J.W., Welsh, C.J., Phang, J.M., and Yeh, G.C. (1994) Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Activation of P-glycoprotein as a putative mechanism. Biochem. Pharmacol., 48, 1437-1445.
47. van Zanden, J.J., van der Woude, H., Vaessen, J., Usta, M., Wortelboer, H.M., Cnubben, N.H., and Rietjens, I.M. (2007) The effect of quercetin phase II metabolism on its MRP1 and MRP2 inhibiting potential. Biochem. Pharmacol., 74, 345-351.
48. Imai, Y., Tsukahara, S., Asada, S., and Sugimoto, Y. (2004) Phytoestrogen/ flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res., 64, 4346-4352.
49. Katayama, K., Masuyama, K., Yoshioka, S., Hasegawa, H., Mitsuhashi, J., and Sugimoto, Y. (2007) Flavonoids inhibit breast cancer resistance protein-mediated drug resistance:transporter specificity and structure-activity relationship. Cancer Chemother. Pharmacol., 60, 789-797.
50. Farabegoli, F., Papi, A., Bartolini, G., Ostan, R., and Orlandi, M. (2010) (-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line. Phytomedicine, 17, 356-362.
51. Singh, S., Malik, B.K., and Sharma, D.K. (2007) Protein kinase C in prostate cancer and herbal products:a bioinformatics approach. Int. J. Integrat. Biol., 1, 72-87.
52. Kim, J.E., Kwon, J.Y., Lee, D.E., Kang, N.J., Heo, Y.S., Lee, K.W., and Lee, H.J. (2009) MKK4 is a novel target for the inhibition of tumor necrosis factor-α-induced vascular endothelial growth factor expression by myricetin. Biochem. Pharmacol., 77, 412-421.
53. Lee, K.W., Kang, N.J., Heo, Y.S., Rogozin, E.A., Pugiliese, A., Hwang, M.K., Bowden, G.T., Bode, A.M., Lee, H.J., and Dong, Z. (2008) Raf and MEK protein kinases are direct molecular targets for the chemopreventive effect of quercetin, a major flavonol in red wine. Cancer Res., 68, 946-955.
54. Hwang, M.K., Kang, N.J., Heo, Y.S., Lee, K.W., and Lee, H.J. (2009) Fyn kinase is a direct molecular target of delphinidin for the inhibition of cyclooxygenase-2 expression induced by tumor necrosis factoralpha. Biochem. Pharmacol., 77, 1213-1222.
55. Lamoral-Theys, D., Pottier, L., Dufrasne, F., Neve, J., Dubois, J., Kornienko, A., Kiss, R., and Ingrassia, L. (2010) Natural polyphenols that display anticancer properties through inhibition of kinase activity. Curr. Med. Chem., 17, 812-825.
56. Hwang, J.T., Kwon, D.Y., and Yoon, S.H. (2009) AMP-activated protein kinase:a potential target for the diseases prevention by natural occurring polyphenols. N. Biotechnol., 26, 17-22.
57. Wiseman, H. (2006) Isoflavonoids and human, in Flavonoids:Chemistry, Biochemistry and Applications (eds Ø.M. Andersen and K.R. Markham), CRC Press, Boca Raton, FL, pp. 371-388.
58. Kuiper, G.G., Lemmen, J.G., Carlsson, B., Corton, J.C., Safe, S.H., van der Saag, P.T., van der Burg, B., and Gustafsson, J.A. (1998) Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology, 139, 4252-4263.
59. Ricketts, M.L., Moore, D.D., Banz, W.J., Mezei, O., and Shay, N.F. (2005) Molecular mechanisms of action of the soy isoflavones includes activation of promiscuous nuclear receptors. A review. J. Nutr. Biochem., 16, 321-330.
60. Wang, F., Shing, M., Huen, Y., Tsang, S.Y., and Xue, H. (2005) Neuroactive flavonoids interacting with GABAA receptor complex. Curr. Drug Targets CNS Neurol. Disord., 4, 575-585.
61. Wolfman, C., Viola, H., Paladini, A.C., Dajas, D., and Medina, J.H. (1994) Possible anxiolytic effects of chrysin, a central benzodiazepine receptor ligand isolated from Passiflora coerulea. Pharmacol. Biochem. Behav., 47, 1-4.
62. Viola, H., Wasowski, C., Levi de Stein, M., Wolfman, C., Silveira, R., Dajas, F., Medina, J.H., and Paladini, A.C. (1995) Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine receptors-ligand with anxiolytic effects. Plant Med., 61, 213-216.
63. Huen, M.S., Hui, K.M., Leung, J.W., Sigel, E., Baur, R., Wong, J.T., and Xue, H. (2003) Naturally occurring 2'-hydroxyl-substituted flavonoids as high-affinity benzodiazepine site ligands. Biochem. Pharmacol., 66, 2397-2407.
64. Johnston, G.A. (2005) GABA(A) receptor channel pharmacology. Curr. Pharm. Des, 11, 1867-1885.
65. Dekermendjian, K., Kahnberg, P., Witt, M.R., Sterner, O., Nielsen, M., and Liljefors, T. (1999) Structure-activity relationships and molecular modeling analysis of flavonoids binding to the benzodiazepine site of the rat brain GABA(A) receptor complex. J. Med. Chem., 42, 4343-4350.
66. Denison, M.S., Phelan, D., and Elferink, C.J. (1998) The Ah receptor signal transduction pathway, in Toxicant-Receptor Interactions (eds M.S. Denison and W.G. Helferich), Taylor & Francis, Philadelphia, PA, pp. 3-33.
67. Zhang, S., Qin, C., and Safe, S.H. (2003) Flavonoids as aryl hydrocarbon receptor agonists/antagonists:effects of structure and cell context. Environ. Health Perspect., 111, 1877-1882.
68. Amakura, Y., Tsutsumi, T., Sasaki, K., Nakamura, M., Yoshida, T., and Maitani, T. (2008) Influence of food polyphenols on aryl hydrocarbon receptor-signaling pathway estimated by in vitro bioassay. Phytochemistry, 69, 3117-3130.
69. Ioannides, C. and Parke, D.V. (1993) Induction of cytochrome P4501 as an indicator of potential chemical carcinogenesis. Drug Metab. Rev., 25, 485-501.
70. Hodek, P., Trefil, P., and Stiborova, M. (2002) Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chem. Biol. Interact., 139, 1-21.
71. Krizkova, J., Burdova, K., Hudecek, J., Stiborova, M., and Hodek, P. (2008) Induction of cytochromes P450 in small intestine by chemopreventive compounds. Neuro Endocrinol. Lett., 29, 717-721.
72. Krizkova, J., Burdova, K., Stiborova, M., Kren, V., and Hodek, P. (2009) Effect of selected flavonoids on cytochromes P450 in rat liver and small intestine. Interdisc. Toxicol., 2, 201-204.
73. Awad, H.M., Boersma, M.G., Boeren, S., van Bladeren, P.J., Vervoort, J., and Rietjens, I.M. (2001) Structure-activity study on the quinone/quinone methide chemistry of flavonoids. Chem. Res. Toxicol., 14, 398-408.
74. Shimada, T., Tanaka, K., Takenaka, S., Murayama, N., Martin, M.V., Foroozesh, M.K., Yamazaki, H., Guengerich, F.P., and Komori, M. (2010) Structure-function relationships of inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2C9, and 3A4 by 33 flavonoid derivatives. Chem. Res. Toxicol., 23, 1921-1935.
75. Moon, Y.J., Wang, X., and Morris, M.E. (2006) Dietary flavonoids:effects on xenobiotic and carcinogen metabolism. Toxicol. In Vitro, 20, 187-210.
76. Androutsopoulos, V.P., Papakyriakou, A., Vourloumis, D., Tsatsakis, A.M., and Spandidos, D.A. (2010) Dietary flavonoids in cancer therapy and prevention:substrates and inhibitors of cytochrome P450 CYP1 enzymes. Pharmacol. Ther., 126, 9-20.
77. Lee, H., Yeom, H., Kim, Y.G., Yoon, C.N., Jin, C., Choi, J.S., Kim, B.R., and Kim, D.H. (1998) Structure-related inhibition of human hepatic caffeine N3-demethylation by naturally occurring flavonoids. Biochem. Pharmacol., 55, 1369-1375.
78. Doostdar, H., Burke, M.D., and Mayer, R.T. (2000) Bioflavonoids:selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. Toxicology, 144, 31-38.
79. Henderson, M.C., Miranda, C.L., Stevens, J.F., Deinzer, M.L., and Buhler, D.R. (2000) In vitro inhibition ofhuman P450 enzymes by prenylated flavonoids from hops, Humulus lupulus. Xenobiotica, 30, 235-251.
80. Tsyrlov, I.B., Goldfarb, I.S., and Gelboin, H.V. (1993) Enzyme-kinetic and immunochemical characteristics of mouse cDNA-expressed, microsomal, and purified CYP1A1 and CYP1A2. Arch. Biochem. Biophys., 307, 259-266.
81. Borek-Dohalsk, L., Hodek, P., Sulc, M., and Stiborova, M. (2001) Alpha-naphthoflavone acts as activator and reversible or irreversible inhibitor of rabbit microsomal CYP3A6. Chem. Biol. Interact., 138, 85-106.
82. Ueng, Y.F., Kuwabara, T., Chun, Y.J., and Guengerich, F.P. (1997) Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry, 36, 370-381.
83. 5. Mutat. Res., 545, 37-47.
84. Canivenc-Lavier, M.C., Vernevaut, M.F., Totis, M., Siess, M.H., Magdalou, J., and Suschetet, M. (1996) Comparative effects of flavonoids and model inducers on drug-metabolizing enzymes in rat liver. Toxicology, 114, 19-27.
85. Kim, H.P., Son, K.H., Chang, H.W., and Kang, S. S. (2004) Anti-inflammatory plant flavonoids and cellular action mechanisms. J. Pharm. Sci., 96, 229-245.
86. Kim, J.S., Kim, J.C., Shim, S.H., Lee, E.J., Jin, W., Bae, K., Son, K.H., Kim, H.P., Kang, S.S., and Chang, H.W. (2006) Chemical constituents of the root of Dystaenia takeshimana and their anti-inflammatory activity. Arch. Pharm. Res., 29, 617-623.
87. Van Hoorn, D.E., Nijveldt, R.J., Van Leeuwen, P.A., Hofman, Z., M'Rabet, L., De Bont, D.B., and Van Norren, K. (2002) Accurate prediction of xanthine oxidase inhibition based on the structure of flavonoids. Eur. J. Pharmacol., 451, 111-118.
88. Williams, R.J., Spencer, J.P., and Rice-Evans, C. (2004) Flavonoids:antioxidants or signalling molecules? Free Radic. Biol. Med., 36, 838-849.
89. Spencer, J.P.E., Schroeter, H., and Rice-Evans, C.A. (2003) Cytoprotective and cytotoxic effects of flavonoids, in Flavonoids in Health and Disease (eds L. Packer and C.A. Rice-Evans), Dekker, New York, pp. 309-349.
90. Matsuo, M., Sasaki, N., Saga, K., and Kaneko, T. (2005) Cytotoxicity of flavonoids toward cultured normal human cells. Biol. Pharm. Bull., 28, 253-259.
91. Andres, A., Donovan, S.M., and Kuhlenschmidt, M.S. (2009) Soy isoflavones and virus infections. J. Nutr. Biochem., 20, 563-569.
92. Evers, D.L., Chao, C.F., Wang, X., Zhang, Z., Huong, S.M., and Huang, E.S. (2005) Human cytomegalovirus-inhibitory flavonoids:studies on antiviral activity and mechanism of action. Antiviral Res., 68, 124-134.
93. Yamaguchi, K., Honda, M., Ikigai, H., Hara, Y., and Shimamura, T. (2002) Inhibitory effects of (-)-epigallocatechin gallate on the life cycle of human immunodeficiency virus type 1 (HIV-1). Antiviral Res., 53, 19-34.
94. Savi, L.A., Caon, T., de Oliveira, A.P., Sobottka, A.M., Werner, W., Reginatto, F.H., Schenkel, E.P., Barardi, C.R., and Simões, C.M. (2010) Evaluation of antirotavirus activity of flavonoids. Fitoterapia, 81, 1142-1146.
95. Alvarez, M.A., Debattista, N.B., and Pappano, N.B. (2008) Antimicrobial activity and synergism of some substituted flavonoids. Fol. Microbiol., 53, 23-28.
96. Saleem, M., Nazir, M., Ali, M.S., Hussain, H., Lee, Y.S., Riaz, N., and Jabbar, A. (2010) Antimicrobial natural products:an update on future antibiotic drug candidates. Nat. Prod. Rep., 27, 238-254.
97. Kuete, V., Nguemeving, J.R., Beng, V.P., Azebaze, A.G., Etoa, F.X., Meyer, M., Bodo, B., and Nkengfack, A.E. (2007) Antimicrobial activity of the methanolic extracts and compounds from Vismia laurentii De Wild (Guttiferae). J. Ethnopharmacol., 109, 372-379.
98. Sathiamoorthy, B., Gupta, P., Kumar, M., Chaturvedi, A.K., Shukla, P.K., and Maurya, R. (2007) New antifungal flavonoid glycoside from Vitex negundo. Bioorg. Med. Chem. Lett., 17, 239-242.
99. Rathee, P., Chaudhary, H., Rathee, S., Rathee, D., Kumar, V., and Kohli, K. (2009) Mechanism of action of flavonoids as anti-inflammatory agents:a review. Inflamm. Allergy Drug Targets, 8, 229-235.
100. Manthey, J.A., Grohmann, K., Montanari, A., Ash, K., and Manthey, C.L. (1999) Polymethoxylated flavones derived from citrus suppress tumor necrosis factor-α expression by human monocytes. J. Nat. Prod., 62, 441-444.
101. Tsai, S.-H., Liang, Y.-C., Lin-Shiau, S.-Y., and Lin, J.-K. (1999) Suppression of TNFα-mediated NFkB activity by myricetin and other flavonoids through downregulating the activity of IKK in ECV304 cells. J. Cell. Biochem., 74, 606-615.
102. Vita, J.A. (2005) Polyphenols and cardiovascular disease:effects on endothelial and platelet function. Am. J. Clin. Nutr., 81, 292S-297S.
103. Freedman, J.E., Parker, C., 3rd, Li, L., Perlman, J.A., Frei, B., Ivanov, V., Deak, L.R., Iafrati, M.D., and Folts, J.D. (2001) Select flavonoids and whole juice from purple grapes inhibit platelet function and enhance nitric oxide release. Circulation, 103, 2792-2798.
104. Ostertag, L.M., O'Kennedy, N., Kroon, P.A., Duthie, G.G., and de Roos, B. (2010) Impact of dietary polyphenols on human platelet function-a critical review of controlled dietary intervention studies. Mol. Nutr. Food Res., 54, 60-81.
105. Drewnowski, A. and Gomez-Carneros, C. (2000) Bitter taste, phytonutrients, and the consumer:a review. Am. J. Clin. Nutr., 72, 1424-1435.
106. Bohm, B.A. (1998) Human use of flavonoids, in Introduction to Flavonoids (ed. B.A. Bohm), Harwood, Amsterdam, pp. 365-395.
107. Le Marchand, L. (2002) Cancer preventive effects of flavonoids-a review. Biomed. Pharmacother., 56, 296-301.
108. Kalra, E.K. (2003) Nutraceutical-definition and introduction. AAPS PharmSci., 5, 27-28.
109. Ramelet, A.A. (2001) Clinical benefits of Daflon 500 mg in the most severe stages of chronic venous insufficiency. Angiology, 52, S49-S56.
110. Meyskens, F.L., Jr and Szabo, E. (2005) Diet and cancer:the disconnect between epidemiology and randomized clinical trials. Cancer Epidemiol. Biomarkers Prev., 14, 1366-1369.
111. Schroeter, H., Spencer, J.P., Rice-Evans, C., and Williams, R.J. (2001) Flavonoids protect neurons from oxidized low-den sity-lipoprotein-induced apoptosis involving c-Jun N-terminal kinase (JNK), c-Jun and caspase-3. Biochem. J., 358, 547-557.
112. Kale, A., Gawande, S., and Kotwal, S. (2008) Cancer phytotherapeutics:role for flavonoids at the cellular level. Phytother. Res., 22, 567-577.
113. Chan, H.Y., Chen, Z.Y., Tsang, D.S., and Leung, L.K. (2002) Baicalein inhibits DMBA-DNA adduct formation by modulating CYP1A1 and CYP1B1 activities. Biomed. Pharmacother., 56, 269-275.
114. Boyd, C.S. and Cadenas, E. (2003) Mitochondrial actions of flavonoids and isoflavonoids, in Flavonoids in Health and Disease (eds L. Packer and C.A. Rice-Evans), Dekker., New York, pp. 273-301.
115. Boots, A.W., Li, H., Schins, R.P., Duffin, R., Heemskerk, J.W., Bast, A., and Haenen, G.R. (2007) The quercetin paradox. Toxicol. Appl. Pharmacol., 222, 89-96.
116. Rahman, A., Shahabuddin, A., Hadi, S.M., and Parish, J.H. (1990) Complexes involving quercetin, DNA and Cu(II). Carcinogenesis, 11, 2001-2003.
117. Galati, G. and O'Brien, P.J. (2004) Potential toxicity of flavonoids and other dietary phenolics:significance for their chemopreventive and anticancer properties. Free Radic. Biol. Med., 37, 287-303.
118. Hsieh, C.Y., Santell, R.C., Haslam, S.Z., and Helferich, W.G. (1998) Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res., 58, 3833-3838.
119. Gaitan, E., Cooksey, R.C., Legan, J., and Lindsay, R.H. (1995) Antithyroid effects in vivo and in vitro of vitexin:a C-glucosylflavone in millet. J. Clin. Endocrinol. Metab., 80, 1144-1147.
120. Román, G.C. (2007) Autism:transient in utero hypothyroxinemia related to maternal flavonoid ingestion during pregnancy and to other environmental antithyroid agents. J. Neurol. Sci., 262, 15-26.
121. Fresco, P., Borges, F., Diniz, C., and Marques, M.P. (2006) New insights on the anticancer properties of dietary polyphenols. Med. Res. Rev., 26, 747-766.
122. Schwarz, D. and Roots, I. (2003) In vitro assessment of inhibition by natural polyphenols of metabolic activation of procarcinogens by human CYP1A1. Biochem. Biophys. Res. Commun., 303, 902-907.
123. Stiborova, M., Frei, E., Hodek, P., Wiessler, M., and Schmeiser, H.H. (2005) Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer. Int.J. Cancer, 113, 189-197.
124. Hodek, P., Tepla, M., Krizkova, J., Sulc, M., and Stiborova, M. (2009) Modulation of cytochrome P450 enzyme system by selected flavonoids. Neuro Endocrinol. Lett., 30, S67-S71.
125. Conney, A.H. (2003) Enzyme induction and dietary chemicals as approaches to cancer chemoprevention:the Seventh DeWitt S. Goodman Lecture. Cancer Res., 63, 7005-7031.
126. Gurtoo, H.L., Koser, P.L., Bansal, S.K., Fox, H.W., Sharma, S.D., Mulhern, A.I., and Pavelic, Z.P. (1985) Inhibition of aflatoxin B1-hepatocarcinogenesis in rats by β-naphthoflavone. Carcinogenesis, 6, 675-678.
127. Nakagama, H., Nakanishi, M., and Ochiai, M. (2005) Modeling human colon cancer in rodents using a food-borne carcinogen, PhIP. Cancer Sci., 96, 627-636.
128. Chen, Y., Xiao, P., Ou-Yang, D.S., Fan, L., Guo, D., Wang, Y.N., Han, Y., Tu, J.H., Zhou, G., Huang, Y.F., and Zhou, H.H. (2009) Simultaneous action of the flavonoid quercetin on cytochrome P450 (CYP) 1A2, CYP2A6, N-acetyltransferase and xanthine oxidase activity in healthy volunteers. Clin. Exp. Pharmacol. Physiol., 36, 828-833.
129. Ioannides, C. (2002) Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica, 32, 451-478.
130. Izzo, A.A. and Ernst, E. (2009) Interactions between herbal medicines and prescribed drugs:an updated systematic review. Drugs, 69, 1777-1798.
131. Schumacher, M., Hautzinger, A., Rossmann, A., Holzhauser, S., Popovic, D., Hertrampf, A., Kuntz, S., Boll, M., and Wenzel, U. (2010) Chrysin blocks topotecan-induced apoptosis in Caco-2 cells in spite of inhibition of ABC-transporters. Biochem. Pharmacol., 80, 471-479.
132. Obach, R.S. (2000) Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression. J. Pharmacol. Exp. Ther., 294, 88-95.
133. Venkataramanan, R., Ramachandran, V., Komoroski, B.J., Zhang, S., Schiff, P.L., and Strom, S.C. (2000) Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab. Dispos., 28, 1270-1273.
134. Doehmer, J., Tewes, B., Klein, K.U., Gritzko, K., Muschick, H., and Mengs, U. (2008) Assessment of drug-drug interaction for silymarin. Toxicol. In Vitro, 22, 610-617.
135. Bailey, D.G., Dresser, G.R., Kreeft, J.H., Munoz, C., Freeman, D.J., and Bend, J.R. (2000) Grapefruit-felodipine interaction:effect of unprocessed fruit and probable active ingredients. Clin. Pharmacol. Ther., 68, 468-477.
136. Paine, M.F., Widmer, W.W., Hart, H.L., Pusek, S.N., Beavers, K.L., Criss, A.B., Brown, S.S., Thomas, B.F., and Watkins, P.B. (2006) A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. Am. J. Clin. Nutr., 83, 1097-1105.
137. Bracke, M.E., Depypere, H.T., Boterberg, T., Van Marck, V.L., Vennekens, K.M., Vanluchene, E., Nuytinck, M., Serreyn, R., and Mareel, M.M. (1999) Influence of tangeretin on tamoxifen's therapeutic benefit in mammary cancer. J. Natl. Cancer Inst., 91, 354-359.
138. Shen, F., Xue, X., and Weber, G. (1999) Tamoxifen and genistein synergistically down-regulate signal transduction and proliferation in estrogen receptor-negative human breast carcinoma MDA-MB-435 cells. Anticancer Res., 19, 1657-1662.
139. Wang, B., Sanchez, R.I., Franklin, R.B., Evans, D.C., and Huskey, S.E. (2004) The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab. Dispos., 32, 1209-1212.
140. m isoform mediating the 3-O-sulfation of ethinyl estradiol. Drug Metab. Dispos., 32, 1299-1303.
141. Miyano, J., Yamamoto, S., Hanioka, N., Narimatsu, S., Ishikawa, T., Ogura, K., Watabe, T., Nishimura, M., Ueda, N., and Naito, S. (2005) Involvement of SULT1A3 in elevated sulfation of 4-hydroxypropranolol in Hep G2 cells pretreated with beta-naphthoflavone. Biochem. Pharmacol., 69, 941-950.
142. Jang, S.I., Kim, H.J., Hwang, K.M., Jekal, S.J., Pae, H.O., Choi, B.M., Yun, Y.G., Kwon, T.O., Chung, H.T., and Kim, Y.C. (2003) Hepatoprotective effect of baicalin, a major flavone from Scutellaria radix, on acetaminophen-induced liver injury in mice. Immunopharmacol. Immunotoxicol., 25, 585-594.
143. Taur, J.S. and Rodriguez-Proteau, R. (2008) Effects of dietary flavonoids on the transport of cimetidine via P-glycoprotein and cationic transporters in Caco-2 and LLC-PK1 cell models. Xenobiotica, 38, 1536-1550.
144. Choi, J.S., Choi, H.K., and Shin, S.C. (2004) Enhanced bioavailability of paclitaxel after oral coadministration with flavone in rats. Int. J. Pharm., 275, 165-170.
145. Wang, Y.H., Chao, P.D.L., Hsiu, S.L., Wen, K.C., and Hou, Y.C. (2004) Lethal quercetin-digoxin interaction in pigs. Life Sci, 74, 1191-1197.
146. Xing, J., Chen, X., Sun, Y., Luan, Y., and Zhong, D. (2005) Interaction of baicalin and baicalein with antibiotics in the gastrointestinal tract. J. Pharm. Pharmacol., 57, 743-750.